IBB Ventures funds Charité, MDC spinout MyoPax in first B# Plus pre-seed round

• MyoPax secured B# Plus pre-seed funding from IBB Beteiligungsgesellschaft mbH’s IBB Ventures, marking the first deal under the new variant.
• The Berlin biotech develops a platform combining regenerative muscle stem cell therapy with CRISPR/Cas gene repair for genetic muscle-wasting diseases.
• Funding supports scale-up of the manufacturing process for pharmaceutical production, preparing the company for an initial clinical trial.
• The round complements prior backing from the European Union’s EIC Accelerator program.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. IBB Beteiligungsgesellschaft mbH published the original content used to generate this news brief on October 13, 2026, and is solely responsible for the information contained therein.